(211 days)
AutoDimer Assay is an immunoturbidimetric assay used for the quantitative determination of the fibrin degradation product D-dimer (in human plasma) using the Hitachi 911, Hitachi 902, or Hitachi 717 instruments. Laboratory measurements of D-dimer have been shown to be of significance in the assessment of pulmonary embolism, deep vein thrombosis and disseminated intravascular coagulation.
AutoDimer Assay is an immunoturbidimetric assay used for the quantitative determination of the fibrin degradation product D-dimer (in human plasma) using the Hitachi 911, Hitachi 902, or Hitachi 717 instruments. AutoDimer Assay utilizes antibody-coated latex particles. The antibody-coated particles are coated with a monoclonal antibody reacting with fibrin D-dimer or fragment D of fibrinogen but not with fibrinogen, allowing D-dimer determination in human plasma.
This FDA 510(k) clearance letter (K012755) for the AutoDimer Assay primarily focuses on establishing substantial equivalence to a predicate device. It does not contain the detailed study information regarding acceptance criteria and performance metrics typically found in a full submission. The provided text is a summary letter, not the full submission itself.
Therefore, I cannot provide the requested information such as:
- A table of acceptance criteria and reported device performance.
- Sample sizes, data provenance, number of experts for ground truth, adjudication method, MRMC study details, standalone performance, or training set information.
The document states:
- Device Name: AutoDimer Assay
- Regulation Number: 21 CFR § 864.7320 (Fibrinogen/Fibrin Degradation Products Assay)
- Regulatory Class: II
Indications For Use (as per the document):
"AutoDimer Assay is an immunoturbidimetric assay used for the quantitative determination of the fibrin degradation product D-dimer in human plasma, using the Hitachi 911, Hitachi 902, and Hitachi 904 instruments. AutoDimer Assay utilizes antibody-coated latex particles. The antibodies are coated with a monoclonal antibody reacting with fibrin D-dimer or fragment D of fibrinogen but not with with Fibrinogen, allowing D-dimer determination in human plasma. Laboratory measurements of D-dimer have been shown to be of significance in the assessment of pulmonary embolism, deep venous thrombosis and disseminated intravascular coagulation."
To obtain the detailed study information, one would need to access the full 510(k) submission for K012755, which is not provided in the given text.
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, facing to the right. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Patrick J. O'Leary, Ph.D. Vice President/General Manager Xtrana, Inc. 6025 Nicolle Street Ventura, California 93003
MAR 1 5 2002
K012755 Re:
Trade/Device Name: AutoDimer Assay Regulation Number: 21 CFR § 864.7320 Regulation Name: Fibrinogen/Fibrin Degradation Products Assay Regulatory Class: II Product Code: DAP Dated: February 8, 2002 Received: February 11, 2002
Dear Dr. O'Leary:
We have reviewed your Section 510(k) premarket notification of intent to market the device we nave reviewed your becaller is substantially equivalent (for the indications ferenced above and nave acteringedly marketed predicate devices marketed in interstate for use stated in the encrosule) to regarry interest and the Medical Device American of to commence provision to May 20, 1978, the oncordance with the provisions of the Federal Food, Drug, devices that have occh recuired in asses approval of a premarket approval application (PMA). and Cosmetic Act (Act) market the device, subject to the general controls provisions of the Act. The You may, therefore, market are act include requirements for annual registration, listing of general controls provisions of the 110 labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your device is classified (see above) this existing major regulations affecting your device can
may be subject to such additional controls. Existing major regulation FDA may be subject to such additions, Title 21, Parts 800 to 898. In addition, FDA may be found in the Out of I outers stogening your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please oe advised that I DA s issuation of a backed complies with other requirements of the Act
that FDA has made a determination that your device complies with other require that TDA has Inade a decommancin and Joinistered by other Federal agencies. You must of any I edital statutes and regulations and and limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set CITY art 807), adomig (21 OFR Part 820), and if applicable, the electronic forth in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Page_1_of_1_
510(k) Number (if known): K012755
Device Name: AutoDimer Assay_
Indications For Use:
AutoDimer Assay is an immunoturbidimetric assay used for the AutoDimer Assay 15 an Intalion of the fibrin degradation product Qualitreactic develminma, using the Hitachi 911, Hitachi 902, D-dimer In numan prasma) abing one in anstruments.
AutoDimer Assay utilizes antibody-coated latex particles. The Autobiller Assur dorities are coated with a monoclonal antibody reacting with fibrin D-dimer or fragment D of fibrinogen but not with with Fibringen, allowing D-dimer determination in human plasma.
Laboratory measurements of D-dimer have been shown to be of significance in the assessment of pulmonary embolism, deep significans and disseminated intravascular coagulation.
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number Koi7755
(Please Do NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Optional Format 3-10-98)
§ 864.7320 Fibrinogen/fibrin degradation products assay.
(a)
Identification. A fibrinogen/fibrin degradation products assay is a device used to detect and measure fibrinogen degradation products and fibrin degradation products (protein fragments produced by the enzymatic action of plasmin on fibrinogen and fibrin) as an aid in detecting the presence and degree of intravascular coagulation and fibrinolysis (the dissolution of the fibrin in a blood clot) and in monitoring therapy for disseminated intravascular coagulation (nonlocalized clotting in the blood vessels).(b)
Classification. Class II (performance standards).